BioCardia Inc. (BioCardia (BCDA)) is having a very good Friday. Shares of the clinical-stage biotech jumped more than 45% after the company announced that the FDA has confirmed its CardiAMP Heart Failure II Trial could be enough to support a Premarket Approval (PMA) application for its cell therapy.

The therapy is designed for patients with ischemic heart failure with reduced ejection fraction (HFrEF) — a condition where the heart doesn't pump blood as well as it should. BioCardia's approach uses a patient's own bone marrow cells, delivered directly to the heart via a minimally invasive catheter procedure. The idea is to increase capillary density and reduce fibrosis in heart tissue, essentially helping the heart heal itself.

The FDA's meeting minutes, released this week, indicate that the ongoing trial could pave the way for market clearance. That's a big deal for a company that's still in the clinical stage and has been burning cash while waiting for a regulatory breakthrough.

And it's not just the FDA that's showing interest. Japan's Pharmaceutical and Medical Device Agency has also indicated that results from three completed clinical trials for ischemic heart failure likely provide enough evidence of safety and efficacy to support a successful submission for approval there. That's a nice international vote of confidence.

Technical Picture: Breaking Out, But Still Climbing a Hill

Friday's surge was a welcome relief for BioCardia shareholders, who have watched the stock slide 33.8% over the past year. But the move has dramatically improved the near-term technical setup.

The stock is now trading 44.5% above its 20-day simple moving average, 29.1% above its 50-day, and 20.4% above its 100-day. That's some serious short-term momentum. More importantly, shares have broken above the 200-day moving average, which sits around $1.33. They're currently about 6.3% above that level. The 200-day exponential moving average near $1.40 is another potential resistance zone.

The MACD indicator — which measures momentum — is above its signal line with a positive histogram, suggesting buying pressure is still building. Traders are now watching the $1.50 level as a key resistance point. It's a round number, and those often act as psychological barriers. On the downside, support is around $1.00, which lines up with the 20-day and 50-day moving averages.

At the time of publication, BioCardia shares were trading at $1.20, up 45.71% on the day. That's a big move for a stock that's been struggling, but it shows what can happen when regulatory news breaks the right way.